71
Participants
Start Date
November 8, 2017
Primary Completion Date
July 27, 2022
Study Completion Date
March 29, 2023
Tinostamustine 60mg/m2 over 30min
Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Tinostamustine 80mg/m2 over 30min
Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Tinostamustine 100mg/m2 over 30min
Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Tinostamustine 60mg/m2 over 60min
Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Tinostamustine 80mg/m2 over 60min
Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Tinostamustine 100mg/m2 over 60min
Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Tinostamustine 80mg/m2 over 80min
Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
Erasmus MC Kanker Instituut, Rotterdam
New York University, New York
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Hospital Universitario La Paz, Madrid
University of Michigan, Ann Arbor
Mary Crowley Cancer Research, Dallas
Cedars-Sinai Medical Center, Los Angeles
Stanford University Medical Center, Palo Alto
Juravinski Cancer Centre, Hamilton
McGill University, Montreal
BC Cancer-Vancouver, Vancouver
Istituto Europeo di Oncologia, Milan
Hospital Universitari Vall d'Hebron, Barcelona
Mundipharma Research Limited
INDUSTRY